Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.
View HTML
Toggle Summary Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the
View HTML
Toggle Summary Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop
SOUTH SAN FRANCISCO, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that four presentations regarding the company's
View HTML
Toggle Summary Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors
SOUTH SAN FRANCISCO, Calif. , April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of
View HTML
Toggle Summary Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
No Significant CA4P Drug Safety Issues Identified Initial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control Arm Enrollment in the Study Continuing SOUTH SAN FRANCISCO, Calif. , April 18, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
SOUTH SAN FRANCISCO, Calif. , March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that updates on several of its preclinical programs are
View HTML
Toggle Summary Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results
SOUTH SAN FRANCISCO, Calif. , March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial
View HTML
Toggle Summary Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
One patient of four (25%) achieved a complete remission No dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
View HTML
Toggle Summary Mateon Therapeutics to Present at 29th Annual ROTH Conference
Presentation on Wednesday, March 15, 2017 at 7:30 am PT
View HTML
Toggle Summary Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completion Three additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity SOUTH SAN FRANCISCO, Calif. , Feb.
View HTML